Riskpilot← Back to searchSign inGet full accessOBA-PHARMA ApS
APSActiveCVR 19995607Sølvgade 23, st.Wholesale of pharmaceutical and medical goods · NACE 4646Est. 1997— employees
Revenue 2025
DKK 2M
-42% vs 2024
EBITDA margin
100.0%
-42% vs 2024
Equity ratio
21.2%
Financial strength
Net profit 2025
DKK 1,5M
-45% vs 2024
| Revenue | DKK 2M | -42% |
| EBITDA | DKK 2M | -42% |
| Net profit | DKK 1,5M | -45% |
| Total assets | DKK 7,6M | +28% |
| Equity | DKK 1,6M | +138% |
| Employees | — | — |
Legal name
OBA-PHARMA ApS
CVR number
19995607
Legal form
Anpartsselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. april 1997
Share capital
DKK 125.000
Employees
—
VAT registered
Yes
Audit selected
Yes
Last report
2025-06-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er handel og investering og dermed beslægtet virksomhed.
Address
Sølvgade 23, st.
Phone
+4533326647
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.971 | 2.901 | 3.665 | 3.226 | 2.809 | 2.771 | 2.522 | 2.253 | 1.120 | 1.334 | 1.041 | 2.853 | 3.402 | 1.988 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 2.489 | 2.901 | 3.665 | 3.226 | 2.809 | 2.771 | 2.522 | 2.253 | 1.120 | 1.334 | 1.041 | 2.853 | 3.402 | 1.988 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 2.489 | 2.901 | 3.665 | 3.226 | 2.809 | 2.771 | 2.522 | 2.253 | 1.120 | 1.334 | 1.041 | 2.853 | 3.402 | 1.988 |
| Net financials | 462 | 241 | 467 | 30 | 20 | -51 | 133 | 60 | -3 | -49 | -76 | -193 | 22 | -103 |
| Profit before tax | 2.950 | 3.142 | 4.132 | 3.256 | 2.829 | 2.720 | 2.654 | 2.312 | 1.117 | 1.284 | 966 | 2.660 | 3.424 | 1.885 |
| Tax | 738 | 786 | 1.012 | 765 | 623 | 564 | 584 | 509 | 252 | 283 | 213 | 586 | 753 | 409 |
| Net profit | 2.213 | 2.356 | 3.120 | 2.491 | 2.207 | 2.155 | 2.070 | 1.804 | 865 | 1.002 | 752 | 2.073 | 2.671 | 1.476 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 10.173 | 5.657 | 6.554 | 5.257 | 5.460 | 6.699 | 8.757 | 4.456 | 3.205 | 4.889 | 6.613 | 11.594 | 5.880 | 7.550 |
| Equity | 7.623 | 2.979 | 3.598 | 3.089 | 2.796 | 4.429 | 6.498 | 2.302 | 1.167 | 2.169 | 1.921 | 2.245 | 674 | 1.602 |
| Long-term debt | 736 | 784 | 1.008 | 0 | 0 | 564 | 0 | 0 | 252 | 283 | 213 | 586 | 753 | 0 |
| Short-term debt | 1.815 | 1.894 | 1.947 | 2.168 | 2.664 | 1.706 | 2.258 | 2.154 | 1.786 | 2.437 | 4.479 | 8.762 | 4.452 | 5.948 |
| Total debt | 2.551 | 2.678 | 2.955 | 2.168 | 2.664 | 2.270 | 2.258 | 2.154 | 2.038 | 2.720 | 4.692 | 9.349 | 5.206 | 5.948 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20122025
Equity ratio
21.2%
This company
38.2%
Market median
-45% vs market
20122025
Return on equity
92.1%
This company
18.4%
Market median
+401% vs market
20122025
Net profit margin
74.2%
This company
8.1%
Market median
+816% vs market
20122025
Asset turnover
0.26×
This company
1.12×
Market median
-77% vs market
20122025
Debt / equity
3.71×
This company
0.62×
Market median
-498% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2024-10-01 – 2025-06-30
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via CVR / Virk · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via CVR / Virk · Period 2016-10-01 – 2017-09-30
- Annual report 2016Filed via CVR / Virk · Period 2015-10-01 – 2016-09-30
- Annual report 2015Filed via CVR / Virk · Period 2014-10-01 – 2015-09-30
- Annual report 2014Filed via CVR / Virk · Period 2013-10-01 – 2014-09-30
- Annual report 2013Filed via CVR / Virk · Period 2012-10-01 – 2013-09-30
- Annual report 2012Filed via CVR / Virk · Period 2011-10-01 – 2012-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PB Management | Management | 1997 | — | — |
OB Management | Management | 1997 | — | — |
MD Management | Management | 2024 | — | — |
KM Audit | Audit | 1997 | — | — |
HA Audit | Audit | 1997 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
NLDB Holding ApS | Company | 50.0% | 50.0% | 2024 |
LEV-VEL ApS | Company | 50.0% | 50.0% | 2024 |
OBA HOLDING ApS | Company | 100.0% | 100.0% | 1997 |
OBNA Holding ApS | Company | 100.0% | 100.0% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NLDB Holding ApS
OBA-PHARMA ApS Board members of OBA-PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Preben Bang Henriksen | Management | 0 companies |
| Ole Birch | Management | 0 companies |
| Malene Dybdahl Birch | Management | 0 companies |
| Kurt Madsen | Audit | 0 companies |
| Harry Aamann | Audit | 0 companies |